COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
作者信息
Camilleri Marquita, Sive Jonathan, Wilson William, Pang Gavin, Jenner Richard, Phillips Elizabeth, Popat Rakesh, Ramasamy Karthik, Bygrave Ceri, Dadaga Tushhar, Streetly Matthew, Cavenagh James, Chapman Mike, Barrington Sally, Pike Lucy, Owen Roger, Clifton-Hadley Laura, Yong Kwee
机构信息
Haematology Department, University College Hospitals, London, UK.
Cancer Institute, University College London, London, UK.
出版信息
Br J Haematol. 2021 Jan;192(1):e14-e16. doi: 10.1111/bjh.17168. Epub 2020 Nov 21.
Abstract
摘要
相似文献
1
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.新型冠状病毒肺炎与骨髓瘤临床研究——来自卡达蒙临床试验的经验
Br J Haematol. 2021 Jan;192(1):e14-e16. doi: 10.1111/bjh.17168. Epub 2020 Nov 21.
2
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.在一项关于卡非佐米、来那度胺、地塞米松和自体干细胞移植的II期试验中，通过质谱法评估多发性骨髓瘤患者外周血中的可测量残留病。
Blood Cancer J. 2021 Feb 5;11(2):19. doi: 10.1038/s41408-021-00418-2.
3
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.卡非佐米、来那度胺、地塞米松和环磷酰胺（KRdc）作为适合移植的新诊断多发性骨髓瘤患者的诱导治疗（Myeloma XI+）：一项开放标签随机对照试验的中期分析。
PLoS Med. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454. eCollection 2021 Jan.
4
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.含卡非佐米的联合方案作为多发性骨髓瘤的一线治疗：13项试验的荟萃分析
Eur J Haematol. 2017 Jun;98(6):601-607. doi: 10.1111/ejh.12877. Epub 2017 Apr 12.
5
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?干细胞移植在多发性骨髓瘤中还有作用吗？
Hematol Oncol Clin North Am. 2024 Apr;38(2):407-420. doi: 10.1016/j.hoc.2023.12.005. Epub 2023 Dec 26.
6
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).一项关于卡非佐米、环磷酰胺和地塞米松作为具有高风险特征的适合移植的多发性骨髓瘤（SGH-MM1）一线治疗方案的2期研究。
Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x.
7
Retinal Pigment Epithelium Tears in a 67-Year-Old Man.
JAMA Ophthalmol. 2018 May 1;136(5):583-584. doi: 10.1001/jamaophthalmol.2017.4445.
8
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.高剂量化疗联合自体造血干细胞移植作为既往自体造血干细胞移植后复发多发性骨髓瘤患者的巩固治疗（NCRI 骨髓瘤 X 复发[强化试验]）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.
9
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.来那度胺联合卡非佐米和地塞米松治疗伴有 t(11,14)(q13;q32)的复发/难治性多发性骨髓瘤：两例病例报告及文献复习。
J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y.
10
[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].异基因骨髓移植后使用卡非佐米、来那度胺和地塞米松联合治疗成功治疗复发/难治性多发性骨髓瘤
Rinsho Ketsueki. 2019;60(10):1468-1470. doi: 10.11406/rinketsu.60.1468.
引用本文的文献
1
The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): A case study of bubonic plague.COVID-19 对被忽视热带病（NTDs）临床研究的影响：以腺鼠疫为例。
PLoS Negl Trop Dis. 2021 Dec 20;15(12):e0010064. doi: 10.1371/journal.pntd.0010064. eCollection 2021 Dec.
2
COVID-19 Virus Infection in Three Patients With Hypogammaglobulinemia.3例低丙种球蛋白血症患者的新型冠状病毒肺炎病毒感染
Cureus. 2021 May 26;13(5):e15256. doi: 10.7759/cureus.15256.
3
COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.接受依库珠单抗治疗的水通道蛋白4视神经脊髓炎患者的新型冠状病毒肺炎
J Neurol. 2021 Dec;268(12):4479-4482. doi: 10.1007/s00415-021-10578-7. Epub 2021 Apr 27.
本文引用的文献
1
Rethinking cancer clinical trials for COVID-19 and beyond.重新思考癌症临床试验在 COVID-19 及以后的应用。
Nat Cancer. 2020 Jun;1(6):568-572. doi: 10.1038/s43018-020-0083-x.
2
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.接受化疗或免疫治疗的血液系统疾病患者发生重症 COVID-19 的临床结局和危险因素。
Br J Haematol. 2020 Oct;191(2):194-206. doi: 10.1111/bjh.17027. Epub 2020 Aug 12.
3
Factors associated with COVID-19-related death using OpenSAFELY.使用 OpenSAFELY 分析与 COVID-19 相关死亡的因素。
Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.
4
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).COVID-19 大流行时代多发性骨髓瘤患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件。
Leukemia. 2020 Aug;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z. Epub 2020 May 22.
Zotero 插件